Favorable outcomes of NPM1mut AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance

I. Khan; A. Kaempf; S. Raghuwanshi; M. Chesnokov; X. Zhang; Z. Wang; A. Domling; J. W. Tyner; C. Camacho; A. L. Gartel

doi:10.1038/s41408-023-00898-4

Favorable outcomes of NPM1^mut AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance

I. Khan, A. Kaempf, S. Raghuwanshi, M. Chesnokov, X. Zhang, Z. Wang, A. Domling, J. W. Tyner, C. Camacho, A. L. Gartel

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Article number	128
Journal	Blood cancer journal
Volume	13
Issue number	1
DOIs	https://doi.org/10.1038/s41408-023-00898-4
State	Published - Dec 2023

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1038/s41408-023-00898-4

Cite this

@article{cc19f5ded9324c86884985aa30015b77,

title = "Favorable outcomes of NPM1mut AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance",

author = "I. Khan and A. Kaempf and S. Raghuwanshi and M. Chesnokov and X. Zhang and Z. Wang and A. Domling and Tyner, {J. W.} and C. Camacho and Gartel, {A. L.}",

note = "Funding Information: This work was funded by NIH1R21TR003587A (ALG) and ACS grant CSDG-21-088-01-ET (IK). ",

year = "2023",

month = dec,

doi = "10.1038/s41408-023-00898-4",

language = "English (US)",

volume = "13",

journal = "Blood cancer journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Favorable outcomes of NPM1mut AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance

AU - Khan, I.

AU - Kaempf, A.

AU - Raghuwanshi, S.

AU - Chesnokov, M.

AU - Zhang, X.

AU - Wang, Z.

AU - Domling, A.

AU - Tyner, J. W.

AU - Camacho, C.

AU - Gartel, A. L.

N1 - Funding Information: This work was funded by NIH1R21TR003587A (ALG) and ACS grant CSDG-21-088-01-ET (IK).

PY - 2023/12

Y1 - 2023/12

UR - http://www.scopus.com/inward/record.url?scp=85168444208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85168444208&partnerID=8YFLogxK

U2 - 10.1038/s41408-023-00898-4

DO - 10.1038/s41408-023-00898-4

M3 - Letter

C2 - 37607920

AN - SCOPUS:85168444208

SN - 2044-5385

VL - 13

JO - Blood cancer journal

JF - Blood cancer journal

IS - 1

M1 - 128

ER -

Favorable outcomes of NPM1mut AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this

Favorable outcomes of NPM1^mut AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance